These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3454800)

  • 21. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer.
    Jauhiainen K; Alfthan O
    Ann Chir Gynaecol; 1984; 73(4):206-10. PubMed ID: 6508201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tumor recurrence prevention using photodynamic therapy after treatment of bladder cancer].
    Sun X; Li H; Wang M
    Zhonghua Wai Ke Za Zhi; 1995 Mar; 33(3):179-80. PubMed ID: 7555391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents.
    Huland E; Arndt R; Huland H
    Cancer Res; 1986 May; 46(5):2488-9. PubMed ID: 3697989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Superficial bladder cancer. Open questions].
    Böhle A
    Urologe A; 1994 Nov; 33(6):536-9. PubMed ID: 7817453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic effect of triethylenethiophosphoramide on the recurrence rate of superficial bladder tumors.
    Mukamel E; Zitron S; Nissenkorn I; Servadio C
    Isr J Med Sci; 1980; 16(9-10):714-6. PubMed ID: 6776072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
    Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superficial TCC bladder cancer: the impact of tumor differentiation on recurrence, progression and survival.
    Kurth KH
    Prog Clin Biol Res; 1984; 162A():307-18. PubMed ID: 6483914
    [No Abstract]   [Full Text] [Related]  

  • 31. [Electron microscopy in the diagnosis and prognosis of transitional-cell bladder tumors].
    Raĭkhlin NT; Romanenko AM; Klimenko IA; Shipilov VI; Iurakh GIu
    Arkh Patol; 1986; 48(4):31-8. PubMed ID: 3718265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 33. [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
    Zhang S; Li H; Cheng H
    Zhonghua Wai Ke Za Zhi; 1995 May; 33(5):304-6. PubMed ID: 7587700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results and long-term course of superficial bladder carcinomas treated with local adriamycin. Apropos of 69 cases].
    Iborra I; Mazcuñán F; Monros JL; Ricos JV; Solsona E
    Arch Esp Urol; 1987 Sep; 40(7):455-60. PubMed ID: 3688987
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J; Palou J; Millán Rodríguez F; Villavicencio Mavrich H; Rodríguez JV
    Arch Esp Urol; 2002; 55(1):50-6. PubMed ID: 11957752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ultrastructure of the basic cell types of human transitional cell bladder cancer].
    Gaĭyrov AG
    Arkh Patol; 1981; 43(6):46-52. PubMed ID: 7271498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
    Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
    Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder.
    Lee E; Schwaibold H; Fradet Y; Huland E; Huland H
    J Urol; 1997 Mar; 157(3):1070-3. PubMed ID: 9072545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.